

KSBi-BIML 2023

Bioinformatics & Machine Learning(BIML)
Workshop for Life Scientists, Data Scientists,
and Bioinformaticians

생물정보학 & 머신러닝 워크샵 (온라인)

Drug Target Prediction and Drug Repositioning with Graph Learning

김선 / 이상선 _ 서울대학교



본 강의 자료는 한국생명정보학회가 주관하는 BIML 2023 워크샵 온라인 수업을 목적으로 제작된 것으로 해당 목적 이외의 다른 용도로 사용할 수 없음을 분명하게 알립니다.

이를 다른 사람과 공유하거나 복제, 배포, 전송할 수 없으며 만약 이러한 사항을 위반할 경우 발생하는 **모든 법적 책임은 전적으로 불법 행위자 본인에게 있음을 경고**합니다.

KSBi-BIML 2023

Bioinformatics & Machine Learning (BIML) Workshop for Life Scientists, Data Scientists, and Bioinformaticians

안녕하십니까?

한국생명정보학회가 개최하는 동계 교육 워크숍인 BIML-2023에 여러분을 초대합니다. 생명정보학 분야의 연구자들에게 최신 동향의 데이터 분석기술을 이론과 실습을 겸비해 전달하고자 도입한 전문 교육 프로그램인 BIML 워크숍은 2015년에 시작하여 올해로 9차를 맞이하게 되었습니다. 지난 2년간은 심각한 코로나 대유행으로 인해 아쉽게도 모든 강의가 온라인으로 진행되어 현장 강의에서만 가능한 강의자와 수강생 사이에 다양한 소통의 기회가 없음에 대한 아쉬움이 있었습니다. 다행히도 최근 사회적 거리두기 완화로 현장 강의를 가능해져 올해는 현장 강의를 재개함으로써 온라인과 현장 강의의 장점을 모두 갖춘 프로그램을 구성할 수 있게 되었습니다.

BIML 워크숍은 전통적으로 크게 인공지능과 생명정보분석 두 개의 분야로 구성되었습니다. 올해 AI 분야에서는 최근 생명정보 분석에서도 응용이 확대되고 있는 다양한 심층학습(Deep learning) 기법들에 대한 현장 강의를 진행될 예정이며, 관련하여 심층학습을 이용한 단백질구조예측, 유전체 분석, 신약개발에 대한 이론과 실습 강의를 함께 제공할 예정입니다. 또한 싱글셀오믹스 분석과 메타유전체분석 현장 강의는 많은 연구자의 연구 수월성 확보에 큰 도움을 줄 것으로 기대하고 있습니다. 이외에 다양한 생명정보학 분야에 대하여 30개 이상의 온라인 강좌가 개설되어 제공되며 온라인 강의의 한계를 극복하기 위해서 실시간 Q&A 세션 또한 마련했습니다. 특히 BIML은 각 분야 국내 최고 전문가들의 강의로 구성되어 해당 분야의 기초부터 최신 연구 동향까지 포함하는 수준 높은 내용의 강의를 될 것입니다.

이번 BIML-2023을 준비하기까지 너무나 많은 수고를 해주신 BIML-2023 운영위원회의 남진우, 우현구, 백대현, 정성원, 정인경, 장혜식, 박종은 교수님과 KOBIC 이병욱 박사님께 커다란 감사를 드립니다. 마지막으로 부족한 시간에도 불구하고 강의 부탁을 흔쾌히 허락하시고 훌륭한 현장 강의와 온라인 강의를 준비하시는데 노고를 아끼지 않으신 모든 연사분께 깊은 감사를 드립니다.

2023년 2월

한국생명정보학회장 이 인 석

Drug Target Prediction and Drug Repositioning with Graph Learning

약물-표적 관계 예측은 신약 개발 초기 단계에 필수적인 기술이며, 기존의 약물을 재활용하는 약물 재창출 분야에도 밀접한 관련이 있는 기술이다. 그렇다면, 약물의 표적은 어떻게 예측할 수 있을까? 이를 바탕으로 약물 재창출은 어떻게 할 수 있을까? In silico 기반의 약물-표적 관계 예측은 약물과 약물, 약물과 질병, 질병과 유전자 등 여러 가지 상호작용을 고려해야 하기에 많은 어려움이 따른다.

본 강의에서는 약물, 질병, 유전자 간 상호작용을 그래프로 학습하여 약물-표적 예측 및 약물 재창출을 설명한다. 먼저 Random walk, Network propagation, Graph neural network 등 기본적인 그래프 분석 기법들을 배우고, 이를 약물-표적 상관관계 분석/예측 및 약물 재창출 분야에서 효율적이고 효과적으로 활용한 최신 사례를 소개한다.

강의는 다음의 내용을 포함한다.

- 그래프 마이닝 알고리즘
- Graph neural network 기반의 딥러닝 기술
- 약물-표적 관계 예측(Drug-Target Interaction) 사례 및 기술
- 약물 재창출(Drug repositioning) 사례 및 기술

* 교육생준비물: X (이론강의)

* 강의 난이도: 중급

* 강의: 김선 교수 (서울대학교 컴퓨터공학부) / 이상선 컴퓨터공학 박사

Curriculum Vitae

Speaker Name: Sun Kim, Ph.D.



► Personal Info

Name Sun Kim
Title Professor
Affiliation Seoul National University (SNU)

► Contact Information

Address Department of Computer Science and Engineering,
301-421, Seoul National University, 1, Gwanak-ro,
Gwanak-gu, Seoul, 08826
Email sunkim.bioinfo@snu.ac.kr

Research Interest

Machine Learning, Deep Learning, Multi-omics, Bioinformatics, AI-drug discovery

Educational Experience

1985 B.S., Computer Science, Seoul National University
1987 M.S., Computer Science, KAIST
1997 Ph.D., Computer Science, University of Iowa

Professional Experience

1998-2001 Senior Computer Scientist, DuPont Central Research
2001-2011 Assistant/Associate Professor, School of Informatics and Computing, Indiana University
2009-2011 Chair, School of Informatics and Computing, Indiana University
2011-2021 Director, Bioinformatics Institute, Seoul National University
2011- Professor, Department of Computer Science and Engineering & Interdisciplinary Program in Bioinformatics, Seoul National University
2022- Research Director, MOGAM Institute for Biomedical Research

Selected Publications (5 maximum)

1. Lee, D., Yang, J., & Kim, S. (2022). Learning the histone codes with large genomic windows and three-dimensional chromatin interactions using transformer. *Nature Communications*, 13(1), 1-19.
2. Lim, S., Lu, Y., Cho, C. Y., Sung, I., Kim, J., Kim, Y., ... & Kim, S. (2021). A review on compound-protein interaction prediction methods: data, format, representation and model. *Computational and Structural Biotechnology Journal*, 19, 1541-1556.
3. Rhee, S., Seo, S., & Kim, S. (2018, July). Hybrid approach of relation network and localized graph convolutional filtering for breast cancer subtype classification. In *Proceedings of the 27th International Joint Conference on Artificial Intelligence* (pp. 3527-3534).
4. Seo, S., Oh, M., Park, Y., & Kim, S. (2018). DeepFam: deep learning based alignment-free method for protein family modeling and prediction. *Bioinformatics*, 34(13), i254-i262.
5. Jo, K., Jung, I., Moon, J. H., & Kim, S. (2016). Influence maximization in time bounded network identifies transcription factors regulating perturbed pathways. *Bioinformatics*, 32(12), i128-i136.

Curriculum Vitae

Speaker Name: Sangseon Lee, Ph.D.



► Personal Info

Name Sangseon Lee
Title Post-doc research fellow
Affiliation Institute of Computer Technology, Seoul National University

► Contact Information

Address 220-653, Seoul National University, 1, Gwanak-ro,
Gwanak-gu, Seoul, 08826
Email sangseon486@snu.ac.kr

Research Interest

Translational bioinformatics, Machine learning and computational genomics

Educational Experience

2013 B.S. in Computer Engineering, Seoul National University, Korea
2020 Ph.D. in Computer Engineering, Seoul National University, Korea

Professional Experience

2020 Postdoctoral research fellow, SNU Bioinformatics Institute
2020-2021 Postdoctoral research fellow, SNU BK21 FOUR Intelligence Computing
2021- Postdoctoral research fellow, SNU Institute of Computer Technology

Selected Publications (5 maximum)

1. Lee, S., Lee, D., Piao, Y., & Kim, S. (2022). SPGP: Structure Prototype Guided Graph Pooling. NeurIPS 2022 Workshop New Frontiers in Graph Learning.
2. Piao, Y., Lee, S., Lee, D., & Kim, S. (2022, June). Sparse Structure Learning via Graph Neural Networks for Inductive Document Classification. In Proceedings of the AAAI Conference on Artificial Intelligence (Vol. 36, No. 10, pp. 11165-11173).
3. Lee, S., Lim, S., Lee, T., Sung, I., & Kim, S. (2020). Cancer subtype classification and modeling by pathway attention and propagation. *Bioinformatics*, 36(12), 3818-3824.
4. Lee, S., Lee, T., Noh, Y. K., & Kim, S. (2019). Ranked k-spectrum kernel for comparative and evolutionary comparison of exons, introns, and cpg islands. *IEEE/ACM transactions on computational biology and bioinformatics*, 18(3), 1174-1183.
5. Lee, S., Park, Y., & Kim, S. (2017). MIDAS: mining differentially activated subpaths of KEGG pathways from multi-class RNA-seq data. *Methods*, 124, 13-24.

Drug Target Prediction and Drug Repositioning with Graph Learning

김선, 이상선

서울대학교
목암생명과학연구소
AIGENDRUG Co. Ltd.

강의 개요

- **Part1 (김선):** 강의개요 (주요 논점)
- **Part2 (이상선):** Preliminary of Graph Learning
- **Part3 (이상선):** Graph Learning for Drug Target Identification
- **Part4 (김선):** Graph Learning for Drug Repurposing

PART 1


강연 개요

3


Why Learning Drug Representation is Difficult?

- **(Issue 1)** Compound graph size vary significantly, which is quite difficult to deal with using GNN.
- **(Issue 2)** Drug has quite a number of properties and learning drug representation is intrinsically multi-task learning.
- Considering two issues together, it is really an open problem to learn drug representation. These challenges are recurring in this lecture.

(예) Graph Learning for Toxicity



Why Learning Drug Representation is Useful?




Learning Drug-Target Interaction

- Given that learning drug representation is difficult, it becomes even more difficult to learn drug-target interaction (DTI) because
 - Drug representation needed to be learned.
 - Representation of target proteins needs to be learned.
- Well, another very complicating factor.
 - DTI should consider what happens after a drug targets a protein (gene) because genes function as a group in a very complex interaction.


7

Summary: Drug-Target Interaction



8

True DTI: Compound-Protein-Cell



9

Drug Re-positioning is Learning Representation of Heterogenous Networks.

- Drug repositioning is to discover unknown association between drug and disease.
- Association between drug and disease is to discover distant relationship.
- Thus, we need help!
- Fortunately, we can use gene networks for this.
- Well, this becomes to learn representation of **three** heterogenous networks: drug – gene – disease.

10

PART 2

Preliminary of Graph Learning

11

Contents

- **What is Graphs?**
 - Example of Graphs in Bioinformatics
- **Preliminary**
 - Random Walk-Based Node Embedding
 - Network Propagation
 - Network Centralities / Clustering
 - VAE / Collective VAE
 - Matrix Factorization
 - Graph Neural Network

12

What is Graph?

- General concept of graph
- Example of graphs in Bioinformatics


13

Graph


- [Mathematics] A structure made of vertices and edges, $G=(V, E)$
- [Abstract Data Type] An abstract data type representing relations or connections

A lot of real-world data does not “live” on grids


Social networks
Citation networks
Communication networks
Multi-agent systems




Protein interaction networks



Knowledge graphs



Molecules




Road maps




Example of Graphs in Bioinformatics - related to DTI & DR

- Relationships between genes, drugs, or diseases




Protein-Protein Interaction (PPI)
Network



Molecular Graph




Protein-Disease Network



Biological Pathway



Drug-Drug Network




Drug-Disease Network


15

Example of Graphs in Bioinformatics - related to DTI & DR


- PPI network & Biological pathway
 - Represents biological mechanisms via gene interactions
 - Can be utilized for learning states of data (ex. patient, cell-line, ...)
- Roles in the DTI & DR tasks
 - Identification of patients or cell-lines through multi-omics data
 - Bridge between drugs and disease



(Mullen, Joseph, et al., *PLoS One*, 2016)




Protein-Protein Interaction
(PPI) Network




Biological Pathway

Example of Graphs in Bioinformatics - related to DTI & DR



Molecular Graph

- Molecular Graph
 - Represents information of drug or small molecule itself
 - Atom types, Bond types, Atom-Atom distance, Bond-Bond angles, ...
- Roles in the DTI & DR tasks
 - Used as inputs for learning drug's structure, function, properties, ..
 - Used as ingredients for calculating drug-drug similarities



(<https://www.intechopen.com/chapters/52373>)

17

Example of Graphs in Bioinformatics - related to DTI & DR


- Drug, Gene, Disease Network
 - Association between drugs, genes, and diseases
- Roles in the DTI & DR tasks
 - Main inputs for learning drug targets and repurposing diseases
 - DTI: which drugs and genes interact?
 - DR: which drugs are used for other diseases?
 - Drug-disease association
 - Discover novel or new targets of approved drugs



Drug-Drug Network



Protein-Disease Network



Drug-Disease Network

18

Preliminary for Graph Learning

- Random Walk-based Node Embedding
- Network Propagation
- Network Centralities / Clustering
- VAE / Collective VAE
- Matrix Factorization
- Graph Neural Network


19

Random Walk-based Node Embedding

20

Random walk


- An agent in the graph moves “randomly” along the graph topology to explore different nodes.



21

Random walk


- An agent in the graph moves “randomly” along the graph topology to explore different nodes.



22

Random walk


- An agent in the graph moves “randomly” along the graph topology to explore different nodes.



23

Random walk



- An agent in the graph moves “randomly” along the graph topology to explore different nodes.



24

Random walk-based Node Embedding

- Inspired by word embedding in natural language processing
 - word2vec: learn word representations by co-occurrence in the sentences
 - Predict context words using a center word




(Li, Bofang, et al., *Data Science and Engineering*, 2019)

(<http://mccormickml.com/2016/04/19/word2vec-tutorial-the-skip-gram-model/>)


Random walk-based Node Embedding

- How to get the sentences from a graph?
 - Random walk!




Random walk-based Node Embedding

- How to get the sentences from a graph?
 - Random walk!



$A \rightarrow B \rightarrow D \rightarrow E \rightarrow G$
 $A \rightarrow D \rightarrow E \rightarrow F \rightarrow D \rightarrow E \rightarrow G$
 $A \rightarrow B \rightarrow C \rightarrow H \rightarrow G$
 $A \rightarrow D \rightarrow E \rightarrow G$

⋮




Make sentences by considering node co-occurrences


27

Random walk-based Node Embedding

- DeepWalk
 - Generate node embeddings using random walks



(a) Input: Karate Graph



(b) Output: Representation

28

(Perozzi, Bryan, Rami Al-Rfou, and Steven Skiena., *ACM SIGKDD*, 2014.)

Random walk-based Node Embedding

- Exploration of graph
 - DFS: Depth-First Search
 - BFS: Breadth-First Search





Figure 1: BFS and DFS search strategies from node u ($k = 3$).

(Grover, Aditya, and Jure Leskovec., ACM SIGKDD, 2016.)

Random walk-based Node Embedding

- Exploration of graph with different probabilities
 - The walk just transitioned from t to v and is now evaluating its next step out of node v .
 - Edge labels indicate search biases α .




(Grover, Aditya, and Jure Leskovec., ACM SIGKDD, 2016.)

Random walk-based Node Embedding

- Exploration of graph with different probabilities
 - The walk just transitioned from t to v and is now evaluating its next step out of node v .
 - Edge labels indicate search biases α .

$p = q = 1$
(special case; DeepWalk)




(Grover, Aditya, and Jure Leskovec., ACM SIGKDD, 2016.)³¹

Random walk-based Node Embedding

- Exploration of graph with different probabilities
 - The walk just transitioned from t to v and is now evaluating its next step out of node v .
 - Edge labels indicate search biases α .

$p = q = 1$
(special case; DeepWalk)

$p > q$
(More explore)




(Grover, Aditya, and Jure Leskovec., ACM SIGKDD, 2016.)³²

Random walk-based Node Embedding

- Exploration of graph with different probabilities
 - The walk just transitioned from t to v and is now evaluating its next step out of node v .
 - Edge labels indicate search biases α .

$p = q = 1$
(special case; DeepWalk)

$p > q$
(More explore)



$p < q$
(walk local)

(Grover, Aditya, and Jure Leskovec., ACM SIGKDD, 2016.)


Random walk-based Node Embedding

- Exploration of graph with different probabilities
 - The walk just transitioned from t to v and is now evaluating its next step out of node v .
 - Edge labels indicate search biases α .

“node2vec”

$p = q = 1$
(special case; DeepWalk)

$p > q$
(More explore)




$p < q$
(walk local)

(Grover, Aditya, and Jure Leskovec., ACM SIGKDD, 2016.)

Random walk-based Node Embedding

- Exploration of graph with different probabilities
 - The walk just transitioned from t to v and is now evaluating its next step out of node v .
 - Edge labels indicate search biases α .




(Grover, Aditya, and Jure Leskovec., ACM SIGKDD, 2016.)

Network Propagation

Network Propagation


- Random walks are generated by transition probabilities.
 - The number of random walks is the number of samples used by the model (DeepWalk, node2vec).
- So what if we create an infinite number of random walks of a certain length from one starting point and then measure the frequency of nodes observed in the walks?



37

Network Propagation

- Propagate information of known nodes (= seeds) via network topology
- Until certain steps, the amount of information (or flow) will be converged




38
(Cowen, Lenore, et al., *Nature Reviews Genetics*, 2017)

Network Propagation

- Propagate information of known nodes (= seeds) via network topology
- Until certain steps, the amount of information (or flow) will be converged
- Random walk with re-start (RWR)


$$p(t + 1) = \alpha \times p(0) + (1 - \alpha) \times W \times p(t)$$



39
(Cowen, Lenore, et al., *Nature Reviews Genetics*, 2017)

Advantages of Network Propagation


- Looking at more distant neighbours that are up to two steps away (yellow; middle panel) again introduces many false positives.
- Network propagation overcomes these problems by simultaneously considering all paths between genes (yellow; right panel).



40
(Cowen, Lenore, et al., *Nature Reviews Genetics*, 2017)

Advantages of Network Propagation

- Network propagation considers and aggregates influence of all seeds via network topology
- It can capture informative clusters of interest




41

(Cowen, Lenore, et al., *Nature Reviews Genetics*, 2017)

Advantages of Network Propagation

- Propagation of the signal from any of the three known disease genes (red) ranks the other known disease genes very highly, owing to the many paths between them.
- Genes in yellow are ranked highly by alternative network analysis methods (which consider direct neighbours or shortest paths); however, these are false positives.



42


(Cowen, Lenore, et al., *Nature Reviews Genetics*, 2017)

Network Centralities / Clustering

43

Network Centralities

- **Centrality** assign numbers or rankings to nodes within a graph corresponding to their network position.
- "What characterizes an important vertex?" → How to define "important"?



Farahani, Farzad V., Waldemar Karwowski, and Nichole R. Lighthall. "Application of graph theory for identifying connectivity patterns in human brain networks: a systematic review." *frontiers in Neuroscience* (2019)

44

Network Centralities

1. Degree Centrality

- defined as the number of links incident upon a node

2. Closeness Centrality

- is the average length of the shortest path between the node and all other nodes in the graph.

3. Betweenness Centrality

- the number of times a node acts as a bridge along the shortest path between two other nodes.


4. Eigenvector Centrality

- Measure of the influence of a node in a network.
- Measured by calculating the eigenvector of adjacency matrix
- Google's PageRank is based on the normalized eigenvector centrality

Farahani, Farzad V., Waldemar Karwowski, and Nichole R. Lighthall. "Application of graph theory for identifying connectivity patterns in human brain networks: a systematic review." *frontiers in Neuroscience* (2019)

45

Network Centralities



Different scores are assigned for different centralities

- A centrality which is optimal for one application is often sub-optimal for a different application.
- The optimal measure depends on the network structure of the most important vertices
- Complex networks (e.g. disease networks) have heterogeneous topology; ranking its nodes with centrality possesses limitations [2].


[1] Wikipedia: Network Centrality (<https://en.wikipedia.org/wiki/Centrality#/media/File:Wp-01.png>, retrieved 2022-11-15)
[2] Lawyer, Glenn. "Understanding the influence of all nodes in a network." *Scientific reports* 5.1 (2015): 1-9.

46

Network Clustering

Disease are interplay of multiple molecular processes

- Disease-associated proteins interact with each other and cluster to form **disease modules**
- Network clustering methods are utilized for detecting communities and modules



Menche, Jörg, et al. "Uncovering disease-disease relationships through the incomplete interactome." *Science* 347.6224 (2015): 1257601.


Network Clustering

Widely-used Network clustering algorithms


1. k-means clustering

- partitions the graph into k clusters based on the location of the nodes such that their distance from the cluster's mean (centroid) is minimum
- The distance is defined using various metrics as Euclidean distance, Euclidean-squared distance, Manhattan distance, or Chebyshev distance.

k-means clustering



Hierarchical clustering



yworks: Clustering Graphs and Networks, <https://www.yworks.com/pages/clustering-graphs-and-networks>


Network Clustering

Widely-used Network clustering algorithms


2. Hierarchical clustering

- Partitions the graph into a hierarchy of clusters.
- The result is a dendrogram which can be cut based on a given cut-off value.

k-means clustering



Hierarchical clustering




yworks: Clustering Graphs and Networks, <https://www.yworks.com/pages/clustering-graphs-and-networks>

Network Clustering

* Limitations of disease module-based approaches

- available interactome and disease-related gene information are incomplete, and do not have sufficient coverage to map out disease modules




Menche, Jörg, et al. "Uncovering disease-disease relationships through the incomplete interactome." *Science* 347.6224 (2015): 1257601.

VAE / Collective VAE

51

Variational Auto-Encoder (VAE)


- A generative model that reconstructs input data from latent variables



52

Variational Auto-Encoder (VAE)

- A generative model that reconstructs input data from latent variables



Kingma, Diederik P., and Max Welling. "Auto-encoding variational bayes." arXiv preprint arXiv:1312.6114 (2013).

53

Collective VAE

- Proposed model for item recommendation
- Simultaneously recover user ratings (main task) and side information
- Can be utilized for DTI & DR
 - Main task: drug-disease association
 - Side Information: drug information




Figure 1: Collective Variational Autoencoder

(Chen, Yifan, and Maarten de Rijke, *Proceedings of the 3rd workshop on deep learning for recommender systems*, 2018.)

54

Matrix Factorization

Matrix Factorization

- A class of collaborative filtering algorithms used in recommender systems.
- Decompose a matrix into two lower dimensional matrices
 - Learn low dimensional latent embeddings of row/column

$$A \approx UV^T$$

$$A \in R^{m \times n} \quad U \in R^{m \times d} \quad V \in R^{n \times d} \quad m, n \gg d$$



Matrix Factorization

- Minimize difference of A and UV^T

$$\min_{U \in \mathbb{R}^{m \times d}, V \in \mathbb{R}^{n \times d}} \sum_{(i,j) \in \text{obs}} (A_{ij} - \langle U_i, V_j \rangle)^2$$



57


<https://developers.google.com/machine-learning/recommendation/collaborative/matrix>

Matrix Factorization

- Minimize difference of A and UV^T
- How to handle unobserved cases?
 - Assume the value as 0.
 - Minimize the loss function with different weights


$$\min_{U \in \mathbb{R}^{m \times d}, V \in \mathbb{R}^{n \times d}} \sum_{(i,j) \in \text{obs}} (A_{ij} - \langle U_i, V_j \rangle)^2 + w_0 \sum_{(i,j) \notin \text{obs}} (\langle U_i, V_j \rangle)^2$$

Observed Only MF



$$\sum_{(i,j) \in \text{obs}} (A_{ij} - U_i \cdot V_j)^2$$

Weighted MF



$$\sum_{(i,j) \in \text{obs}} (A_{ij} - U_i \cdot V_j)^2 + w_0 \sum_{(i,j) \notin \text{obs}} (0 - U_i \cdot V_j)^2$$

58


<https://developers.google.com/machine-learning/recommendation/collaborative/matrix>

Matrix Factorization (\approx Matrix Completion)

- Standard matrix factorization is transductive.

$$\min_{W,H} \sum_{(i,j) \in \Omega} \left(P_{ij} - (WH^T)_{ij} \right)^2 + \frac{\lambda}{2} \left(\|W\|_F^2 + \|H\|_F^2 \right)$$

To prevent overfitting



Example of item recommendation

59

[Beyond Low Rank Matrix Factorization | Center for Big Data Analytics \(utexas.edu\)](#)

Matrix Factorization (\approx Matrix Completion)

- Standard matrix factorization is transductive.


$$\min_{W,H} \sum_{(i,j) \in \Omega} \left(P_{ij} - (WH^T)_{ij} \right)^2 + \frac{\lambda}{2} \left(\|W\|_F^2 + \|H\|_F^2 \right)$$

To prevent overfitting

- All matrix completion approaches suffer from extreme sparsity of the observed matrix and the cold-start problem.

Easy to learn & predict

Hard to learn & predict



60

(Ocepek, Uroš, Jože Rugelj, and Zoran Bosnić., Expert Systems with Applications, 2015.)

Matrix Factorization (\approx Matrix Completion)

- Standard matrix factorization is transductive.

$$\min_{W,H} \sum_{(i,j) \in \Omega} \left(P_{ij} - (WH^T)_{ij} \right)^2 + \frac{\lambda}{2} \left(\|W\|_F^2 + \|H\|_F^2 \right)$$

To prevent overfitting

- Inductive Matrix Factorization (or Completion)
 - Can be interpreted as a generalization of the transductive multi-label formulation

$$\min_{W,H} \sum_{(i,j) \in \Omega} \ell(P_{ij}, \underline{x_i^T} \underline{WH^T} y_j) + \frac{\lambda}{2} \left(\|W\|_F^2 + \|H\|_F^2 \right)$$

61

Matrix Factorization (\approx Matrix Completion)

- Inductive Matrix Factorization (or Completion)
 - Can be interpreted as a generalization of the transductive multi-label formulation

$$\min_{W,H} \sum_{(i,j) \in \Omega} \ell(P_{ij}, x_i^T WH^T y_j) + \frac{\lambda}{2} \left(\|W\|_F^2 + \|H\|_F^2 \right)$$

- Positive-Unlabeled (PU) Matrix Completion
 - In case of DTI task, we collect positive pairs of drug and target protein.
 - It is difficult to “well-defined negative” data.

$$\min_{W,H} \sum_{(i,j) \in \Omega^+} \left(P_{ij} - x_i WH^T y_j \right)^2 + \alpha \sum_{(i,j) \in \Omega^-} \left(P_{ij} - x_i WH^T y_j \right)^2 + \lambda \left(\|W\|_F^2 + \|H\|_F^2 \right)$$

α : the penalty of the unobserved entries toward zero

62


(Zeng, Xiangxiang, et al., Chemical Science, 2020)

Graph Neural Network

63

Graph Neural Network

The bigger picture:




Notation: $\mathcal{G} = (\mathbf{A}, \mathbf{X})$

- Adjacency matrix $\mathbf{A} \in \mathbb{R}^{N \times N}$
- Feature matrix $\mathbf{X} \in \mathbb{R}^{N \times F}$


Main idea: Pass messages between pairs of nodes & agglomerate

Recap: Convolutional Neural Networks (on grids)

Single CNN layer with 3x3 filter:



(Animation by Vincent Dumoulin)



Update for a single pixel:

- Transform messages individually $\mathbf{W}_i \mathbf{h}_i$
- Add everything up $\sum_i \mathbf{W}_i \mathbf{h}_i$

$\mathbf{h}_i \in \mathbb{R}^{l'}$ are (hidden layer) activations of a pixel/node

Full update:


$$\mathbf{h}_4^{(l+1)} = \sigma \left(\mathbf{W}_0^{(l)} \mathbf{h}_0^{(l)} + \mathbf{W}_1^{(l)} \mathbf{h}_1^{(l)} + \dots + \mathbf{W}_8^{(l)} \mathbf{h}_8^{(l)} \right)$$

*slide from Thomas Kipf, University of Amsterdam ⁶⁵


Graph Convolutional Networks (GCNs)

Kipf & Welling (ICLR 2017), related previous works by Duvenaud et al. (NIPS 2015) and Li et al. (ICLR 2016)

Consider this undirected graph:



Calculate update for node in red:



Update rule:
$$\mathbf{h}_i^{(l+1)} = \sigma \left(\mathbf{h}_i^{(l)} \mathbf{W}_0^{(l)} + \sum_{j \in \mathcal{N}_i} \frac{1}{c_{ij}} \mathbf{h}_j^{(l)} \mathbf{W}_1^{(l)} \right)$$

Scalability: subsample messages [Hamilton et al., NIPS 2017]

\mathcal{N}_i : neighbor indices c_{ij} : norm. constant (fixed/trainable)

*slide from Thomas Kipf, University of Amsterdam ⁶⁶


Graph Convolutional Networks (GCNs)

Kipf & Welling (ICLR 2017), related previous works by Duvenaud et al. (NIPS 2015) and Li et al. (ICLR 2016)

Consider this undirected graph:



Calculate update for node in red:



Update rule:
$$\mathbf{h}_i^{(l+1)} = \sigma \left(\mathbf{h}_i^{(l)} \mathbf{W}_0^{(l)} + \sum_{j \in \mathcal{N}_i} \frac{1}{c_{ij}} \mathbf{h}_j^{(l)} \mathbf{W}_1^{(l)} \right)$$

Scalability: subsample messages [Hamilton et al., NIPS 2017]

Vectorized form

$$\mathbf{H}^{(l+1)} = \sigma \left(\mathbf{H}^{(l)} \mathbf{W}_0^{(l)} + \tilde{\mathbf{A}} \mathbf{H}^{(l)} \mathbf{W}_1^{(l)} \right)$$

with $\tilde{\mathbf{A}} = \mathbf{D}^{-\frac{1}{2}} \mathbf{A} \mathbf{D}^{-\frac{1}{2}}$

Or treat self-connection in the same way:

$$\mathbf{H}^{(l+1)} = \sigma \left(\hat{\mathbf{A}} \mathbf{H}^{(l)} \mathbf{W}_1^{(l)} \right)$$

with $\hat{\mathbf{A}} = \tilde{\mathbf{D}}^{-\frac{1}{2}} (\mathbf{A} + \mathbf{I}_N) \tilde{\mathbf{D}}^{-\frac{1}{2}}$

\mathcal{N}_i : neighbor indices c_{ij} : norm. constant (fixed/trainable)

*slide from Thomas Kipf, University of Amsterdam ⁶⁷


Graph Convolutional Networks (GCNs)

Kipf & Welling (ICLR 2017), related previous works by Duvenaud et al. (NIPS 2015) and Li et al. (ICLR 2016)

Consider this undirected graph:



Calculate update for node in red:



Update rule:
$$\mathbf{h}_i^{(l+1)} = \sigma \left(\mathbf{h}_i^{(l)} \mathbf{W}_0^{(l)} + \sum_{j \in \mathcal{N}_i} \frac{1}{c_{ij}} \mathbf{h}_j^{(l)} \mathbf{W}_1^{(l)} \right)$$

Scalability: subsample messages [Hamilton et al., NIPS 2017]

Desirable properties:

- Weight sharing over all locations
- Invariance to permutations
- Linear complexity $O(E)$
- Applicable both in transductive and inductive settings

Limitations:


- Requires gating mechanism / residual connections for depth
- Only indirect support for edge features

\mathcal{N}_i : neighbor indices c_{ij} : norm. constant (fixed/trainable)

*slide from Thomas Kipf, University of Amsterdam ⁶⁸

Classification and link prediction with GNNs/GCNs

Input: Feature matrix $\mathbf{X} \in \mathbb{R}^{N \times E}$, preprocessed adjacency matrix $\hat{\mathbf{A}}$



Node classification:

$\text{softmax}(\mathbf{z}_n)$
e.g. Kipf & Welling (ICLR 2017)

Graph classification:

$\text{softmax}(\sum_n \mathbf{z}_n)$
e.g. Duvenaud et al. (NIPS 2015)

Link prediction:

$p(A_{ij}) = \sigma(\mathbf{z}_i^T \mathbf{z}_j)$
Kipf & Welling (NIPS BDL 2016)
"Graph Auto-Encoders"

*slide from Thomas Kipf, University of Amsterdam ⁶⁹

Various GNNs - Isotropic

- Different *Aggregation* and *Update* functions are utilized for GNNs




Figure 6. GCN Layer




Figure 7. GraphSage Layer




Figure 8. GIN Layer

Various GNNs - Anisotropic

- Different *Aggregation* and *Update* functions are utilized for GNNs
- Learn weights of neighborhoods




Figure 9. GAT Layer




Figure 10. MoNet Layer




Figure 11. GatedGCN Layer

71

Dwivedi, Vijay Prakash, et al. "Benchmarking graph neural networks." arXiv preprint arXiv:2003.00982 (2020).

Summary of Part2

72

Summary

- **Graph**
 - A collection of interactions
 - Contains relationships between drugs, genes, and diseases
 - Heterogenous data types provide rich information but also cause technical challenges
- **Technologies**
 - Random Walk-Based Node Embedding
 - Network Propagation
 - Network Centralities / Clustering
 - VAE / Collective VAE
 - Matrix Factorization
 - Graph Neural Network

73

PART 3

Graph Learning for Drug Target Identification

74

Contents

- Current researches in DTI prediction
- Future directions in DTI prediction
 - Heterogenous drug, gene, disease information
 - Downstream effect of drugs
- Technologies for DTI
 - deepDTnet (Chemical Science, 2020)
 - Drug embedding with target information (Briefings in Bioinformatics, accepted)

75

Current researches in DTI prediction

76



journal homepage: www.elsevier.com/locate/csbj



A review on compound-protein interaction prediction methods: Data, format, representation and model



Sangsoo Lim ^{a,1}, Yijingxiu Lu ^b, Chang Yun Cho ^d, Inyoung Sung ^d, Jungwoo Kim ^b, Youngkuk Kim ^b, Sungjoon Park ^b, Sun Kim ^{a,b,c,d,*}

^a Bioinformatics Institute, Seoul National University, Seoul, Republic of Korea

^b Department of Computer Science and Engineering, College of Engineering, Seoul National University, Seoul, Republic of Korea

^c Institute of Engineering Research, Seoul National University, Seoul, Republic of Korea

^d Interdisciplinary Program in Bioinformatics, College of Natural Sciences, Seoul National University, Seoul, Republic of Korea

Computational and Structural Biotechnology Journal, 2021 (cited 25 times)


77

Review on DTI research

• Background:

- AI approaches such as kernel-based, tree-based classifications, and neural network variations are recently applied to predicting affinity or interactions between small molecular drugs and protein targets.
- DTI researches could be separated into three major parts: data preparation, model training, and prediction.

Overview of DTI prediction processes



78



Review on DTI research

- **Data preparation:**
- Compounds:
 - Chemical compounds can be described naturally in a human-readable format such as strings, graphs, or images.
 - Chemical fingerprints that represents the existence of constitutive substructures/scaffolds or common functional groups are also widely used.
- Proteins:
 - Protein are represented as sequence of amino acids in most recent AI-based DTI researches.
 - To utilize protein 3D structures, it is common to convert it as chemically attributed spatial graphs.
 - Compared to the number of known amino acid sequences, number of known protein structures are much smaller.

79

Review on DTI research

- **Data preparation:**



80


Review on DTI research

- **Model training:**
- Machine learning-based methods:
 - Decision tree, random forest
 - Support vector machine
 - Heterogeneous network
- Deep learning-based methods:
 - Recurrent neural network (RNN), Natural language processing (NLP)
 - Convolutional neural network (CNN)
 - Graph neural network (GNN)
 - Variational autoencoder (VAE) or generative adversarial network (GAN)

81

Typical model architectures for DTI

- **Train compounds and proteins** separately with two independent deep learning modules.
- **Combine latent vectors** of compounds and proteins for interaction prediction.




..ztürk H, ..zğur A, Ozkirimli E. *Bioinformatics*, 2018
 Tsubaki M, Tomii K, Sese J. *Bioinformatics*, 2019.
 Huang K, Fu T, Glass L M, et al. *Bioinformatics*, 2020.

82


Drug – Target interaction needs to consider downstream effects, gene expressions!

Drug-target interactions and gene expression

- Drug molecules intervene in the regulatory process by binding with specific target ligands.
- Traditional treatment design based on physical parameters and external modalities or simple drug-target interactions are not sufficient for meeting clinical drug safety criteria or specifying variability among individuals.
- Modeling of the integrated clinical data and multi-layer molecular interactions makes the drug responses predictable.



A systemic view of disease



Analysis of disease and drug effect

Technologies for DTI

- deepDTnet (Chemical Science, 2020)
- Drug embedding with target information (Briefings in Bioinformatics, accepted)

85

Chemical Science, 2020

Target identification among known drugs by deep learning from heterogenous networks

Xiangxiang Zeng,^{‡a} Siyi Zhu,^{‡b} Weiqiang Lu,^{‡c} Zehui Liu,^{‡d} Jin Huang,^{ID d} Yadi Zhou,^e Jiansong Fang,^e Yin Huang,^{ef} Huimin Guo,^f Lang Li,^g Bruce D. Trapp,^h Ruth Nussinov,^{ID ij} Charis Eng,^{eklmn} Joseph Loscalzo^o and Feixiong Cheng ^{ID *ekl}

86


Motivation

- Drug target identification is a crucial process for drug discovery and effective treatment of human diseases
- Unintended therapeutic effects or multiple drug-target interactions leading to off-target toxicities and suboptimal effectiveness
- Experimental determination of drug-target interactions is costly and time-consuming
- **Challenge**
 - the features learned from the unsupervised learning procedure did not capture non-linearity
 - randomly selected drug–target pairs as negative samples often cause potential false positive rate
- **Approach:** a network-based deep learning for *in silico* identification of molecular targets for known drugs
 - Embeds 15 types of chemical, genomic, phenotypic, and cellular networks
 - Generate biologically and pharmacologically relevant features through learning low-dimensional but informative vectors for both drugs and targets
 - To address the lack of negative samples, they utilized Positive-Unlabeled (PU) setting

87

DeepDTnet

- **DeepDTnet** is a deep learning methodology for new target identification and drug repurposing in a heterogeneous drug–gene–disease network embedding 15 types of chemical, genomic, phenotypic, and cellular network profiles.



88


Model overview

- **Input:**
 - 15 types of chemical, genomic, phenotypic, and cellular networks for 732 drugs and 1,178 targets.
- **Output:**
 - The likelihood of the pairwise interaction score between drugs and targets.
- **Methodology:**
 - DeepDTnet learns low-dimensional vector representation of the features for each node in the heterogeneous network.
 - After learning the feature matrix for drugs and targets, deepDTnet applies PU-matrix completion to find the best projection from the drug space onto target (protein) space.
 - Finally, deepDTnet infers new targets for a drug ranked by geometric proximity to the projected feature vector of the drug in the projected space.

89

Model overview


Learn the low-dimensional vectors for drugs, diseases



90


Heterogenous networks

- Various databases are collected and utilized
 - Ex) drug-target network: DrugBank, Therapeutic Target Database, PharmGKB
 - Ex) disease-gene network: OMIM, CTD, HuGE navigator



91

Step1: low-dimensional representations



92

Probabilistic Co-Occurrence matrix & Positive Pointwise Mutual Information

- Network propagation learns both local and global topological information
- After k step, a **probabilistic co-occurrence matrix** is obtained for each network

$$p_k = \omega \cdot p_{k-1}A + (1 - \omega)p_0$$

- A **positive pointwise mutual information (PPMI)** matrix is calculated to obtain drug representations

$$\text{PPMI} = \max \left(\log \frac{M(i,j) * \sum_i \sum_j M(i,j)}{\sum_i M(i,j) * \sum_j M(i,j)}, 0 \right)$$


M : the original co-occurrence matrix,

N_r : the number of rows

N_c : the number of columns.

93


Step1: low-dimensional representations



Stacked denoising autoencoder is utilized for learning low-dimensional vectors

94

Step2: PU-based matrix completion



Inductive matrix completion

$$\min_{W,H} \sum_{(i,j) \in \Omega} \ell(P_{ij}, x_i^T W H^T y_j) + \frac{\lambda}{2} (\|W\|_F^2 + \|H\|_F^2)$$



PU-matrix completion

$$\min_{W,H} \sum_{(i,j) \in \Omega^+} (P_{ij} - x_i W H^T y_j^T)^2 + \alpha \sum_{(i,j) \in \Omega^-} (P_{ij} - x_i W H^T y_j^T)^2 + \lambda (\|W\|_F^2 + \|H\|_F^2)$$

α : the penalty of the unobserved entries toward zero


95

Results: Performance of DTI prediction



96

Results: The uncovered drug-target network



97

Summary

- Deep learning model for learning heterogeneous drug-gene-disease network
- Key points
 - Learn multiple chemical & genomic information as low-dimensional embeddings
 - Apply PU-matrix completion to address sparsity of positive samples and lack of negative samples in DTI

98

Improved Drug Response Prediction by Drug Target Data Integration via Network-based Profiling

Minwoo Pak^{1,†}, Sangseon Lee^{2,†}, Inyoung Sung³ and Sun Kim^{1,3,4,*}

99


Motivation

- Drug response prediction is important for precision medicine in that it can help predict how a patient would react to a drug before the actual administration
- Intuitively, use of drug target interaction (DTI) information can be useful for drug response prediction
- **Challenge:** use of DTI is difficult because existing drug response database such as CCLE and GDSC do not have information about transcriptome after drug treatment
- **Approach:** framework, NetGP that can improve existing deep learning-based drug response prediction models **by effectively utilizing drug target information.**
 - a module to compute gene perturbation scores by the network propagation technique on a Protein-Protein Interaction (PPI) network
 - NetGP with the network propagation technique produces perturbation effects by the pharmacologic modulation of target gene
 - a model-agnostic way so that any existing DTI tool can be incorporated.

100

Motivation

- **Drug response** prediction is highly significant in precision medicine in that it can help predict how a patient would react to a drug before the actual administration.
- **Drug target information** represents the mechanism of the drug affecting a cell thereby bridging the relationship between the two.



101

*GDSC: Genomics of Drug Sensitivity in Cancer
*CADD: Chemoinformatics Tools and User Services


Model overview

- **Input**
 - Drug response information from GDSC
 - Drug SMILES data from CADD
 - Protein-protein interaction network from STRING
 - Drug target information from GDSC and DrugBank
- **Model**
 - **TargetNet**: drug target profile extraction algorithm
 - **Placeholder** drug response prediction method
- **Output**
 - Drug response: IC50 or area under dose-response curve value

102

Overview of NetGP

- Integration with existing tools in terms of embedding vector (in model-agnostic way)




- Simulate a perturbation effect of a given drug using drug target information and PPI network → network propagation

103

NetGP: Model detail

- Phase 1: network-based drug target profile extraction phase**

NetGP: Drug Target Profile Extraction Algorithm




- Network propagation identifies affected candidate genes from drug target genes
- Iteratively perform network propagation with enriched biological mechanisms
 - Network propagation prunes to biased seeds and network topology
 - Iteration will remove noises

104

NetGP: Model detail

- **Phase 2:** drug target profile integration
 - Embed cell line, drug and drug target profile from NetGP
 - Any deep learning model can be replaced with Placeholder



105

Results: Performance of Drug Response Prediction

- Drug response prediction performance gain by integrating TargetNet
 - 1st row: Placeholder method
 - 2nd row: Placeholder method + NetGP

- Traditional evaluation scheme

Mix Split	RMSE ↓		PCC ↑		SCC ↑	
AGW	1.0345 ± 0.011		0.9237 ± 0.002		0.8987 ± 0.002	
w/ NetGP	1.0328 ± 0.006	+0.19%	0.9238 ± 0.001	+0.01%	0.8988 ± 0.002	+0.01%
DEERS	1.2124 ± 0.020		0.8923 ± 0.004		0.8567 ± 0.004	
w/ NetGP	1.2085 ± 0.015	+0.25%	0.8937 ± 0.003	+0.22%	0.8586 ± 0.004	+0.23%
DeepTTA	0.9988 ± 0.009		0.9284 ± 0.001		0.9045 ± 0.002	
w/ NetGP	0.9979 ± 0.008	+0.10%	0.9284 ± 0.001	-	0.9044 ± 0.002	-0.11%
MLP	1.0734 ± 0.012		0.9169 ± 0.002		0.8914 ± 0.003	
w/ NetGP	1.0201 ± 0.012	+5.20%	0.9251 ± 0.002	+0.87%	0.9001 ± 0.003	+1.01%
Precily	1.2903 ± 0.016		0.8760 ± 0.003		0.8357 ± 0.005	
w/ NetGP	1.0800 ± 0.032	+19.44%	0.9149 ± 0.004	+4.45%	0.8857 ± 0.005	+5.98%
PathDNN	1.4049 ± 0.011		0.8689 ± 0.002		0.8219 ± 0.002	
w/ NetGP	1.3402 ± 0.048	+4.85%	0.8827 ± 0.009	+1.61%	0.8454 ± 0.009	+2.8%

(b) Mix Split

- Unseen drugs during training


Drug Split	RMSE ↓		PCC ↑		SCC ↑	
AGW	2.6053 ± 0.297		0.3683 ± 0.149		0.3373 ± 0.146	
w/ NetGP	2.4837 ± 0.260	+4.87%	0.4374 ± 0.135	+18.75%	0.4079 ± 0.135	+21.07%
DEERS	2.6225 ± 0.375		0.2939 ± 0.132		0.2743 ± 0.108	
w/ NetGP	2.5538 ± 0.315	+2.66%	0.3944 ± 0.105	+34.01%	0.3647 ± 0.084	+33.21%
DeepTTA	2.5096 ± 0.358		0.4241 ± 0.155		0.3771 ± 0.117	
w/ NetGP	2.4086 ± 0.285	+4.19%	0.4675 ± 0.083	+10.38%	0.4399 ± 0.075	+16.71%
MLP	2.5871 ± 0.292		0.3799 ± 0.129		0.3433 ± 0.120	
w/ NetGP	2.4621 ± 0.281	+5.08%	0.4475 ± 0.122	+17.80%	0.4088 ± 0.118	+18.95%
Precily	2.7150 ± 0.240		0.4673 ± 0.125		0.4192 ± 0.134	
w/ NetGP	2.4321 ± 0.265	+11.64%	0.5230 ± 0.143	+11.99%	0.4511 ± 0.118	+7.64%
PathDNN	2.9481 ± 0.384		0.1772 ± 0.230		0.1823 ± 0.224	
w/ NetGP	2.9456 ± 0.289	+0.07%	0.1975 ± 0.158	+11.86%	0.1536 ± 0.160	-15.38%

(a) Drug Split

106

Results: Gene importance analysis

- Drug example: Doxorubicin



107

Results: Effect of Drug Target Information

- Use of drug target profile boosts prediction performance, especially for drugs with explicit target proteins known

Table 3. Explicit Target Drugs vs. Non-explicit Target Drugs. *
* indicates explicit target pathway.

Category	Default	Framework Applied	Difference
↑ Default	0.3154	0.4532	+43.69%
↑ DNA Replication	0.3794	0.3835	+1.08%
↑ Mitosis	0.7467	0.7542	+1.00%
↑ *Other, Kinase	0.3930	0.6959	+77.07%

108

Summary

- Proposed a framework for improved drug response prediction by effectively exploiting drug target information
- Key points
 - Presents a drug target profile extraction algorithm **NetGP**
 - Drug target profile from **NetGP** can be integrated to any exiting drug response prediction deep learning model

109

Summary of Part3

110

Summary

- **Graph Learning for DTI**

- Current DTI studies focus only drugs and targets of interest.
- Learning heterogenous relationships between drugs, genes, and diseases is important.
- Downstream effects of drugs will improve drug-target identification and drug response prediction.

111

PART 4 Drug Repurposing

112

Contents

- **Introduction**
- **Examples**
 - Baricitinib
 - DrugCell
 - Deep learning approach to Antibiotic discovery
 - Literature-based approaches
- **Networks and Databases**
 - **Networks**
 - PPI – STRING, BioGRID
 - Biological pathways – KEGG, Reactome
 - Disease networks – Disesome, HDN, DGN
 - Comprehensive heterogeneous networks – Hetio, MSI
 - **Databases**
 - Drug Repurposing Hub
 - RepoDB
 - CTD
 - PharmacDB
- **Technologies**
 - **Network analysis**
 - Network centralities
 - Network clustering – K-means, Hierarchical
 - Network propagation – PropaNet, MLDEG
 - **Network representation learning**
 - word2vec – DeepWalk, node2vec, DREAMwalk
 - Graph Neural Network
- **Network-based drug repurposing: cases**
 - SNF-cVAE (Knowledge-Based Systems, 2021)
 - CBPred (Cells, 2019)
 - DeepDR (Bioinformatics, 2019)
 - BiFusion (ISMB 2020)
 - DreamWalk (in review)

Drug repositioning (or repurposing)

- Repurposing of old drugs to treat diseases is increasingly becoming an attractive proposition.
- Advantages of repurposing drugs
 - Risk of failure is lower
 - Time frame can be reduced
 - Less investment is needed
 → Less risky and more rapid return in investment!





Table 1 | Selected successful drug repurposing examples and the repurposing approach employed

Drug name	Original indication	New indication	Date of approval	Repurposing approach used	Comments on outcome of repurposing
Zidovudine	Cancer	HIV/AIDS	1987	In vitro screening of compound libraries	Zidovudine was the first anti-HIV drug to be approved by the FDA.
Minoxidil	Hypertension	Hair loss	1988	Retrospective clinical analysis (identification of hair growth as an adverse effect)	Global sales for minoxidil were US\$660 million in 2016 (Quintile minoxidil sales report, 2017; see Related links)
Sildenafil	Angina	Erectile dysfunction	1998	Retrospective clinical analysis	Marketed as Viagra, sildenafil became the leading product in the erectile dysfunction drug market, with global sales in 2017 of \$7.05 billion*
Thalidomide	Morning sickness	Erythema nodosum leprosum and multiple myeloma	1998 and 2000	Off-label usage and pharmacological analysis	Thalidomide derivatives have achieved substantial clinical and commercial success in multiple myeloma.
Celecoxib	Pain and inflammation	Familial adenomatous polyposis	2000	Pharmacological analysis	The total revenue from Celebrex (Pfizer) at the end of 2014 was \$2.63 billion (Euros 2014 financial report; see Related links)
Atomoxetine	Parkinson disease	ADHD	2002	Pharmacological analysis	Strattera (Eli Lilly) recorded global sales of \$935 million in 2016.
Duloxetine	Depression	SUI	2004	Pharmacological analysis	Approved by the EMA for SUI. The application was withdrawn in the US. Duloxetine is approved for the treatment of depression and chronic pain in the US.
Rituximab	Various cancers	Rheumatoid arthritis	2006	Retrospective clinical analysis (remission of coexisting rheumatoid arthritis in patients with non-Hodgkin lymphoma treated with rituximab ¹⁰)	Global sales of rituximab topped \$7 billion in 2015 (see Related links)
Ratofenone	Osteoporosis	Breast cancer	2007	Retrospective clinical analysis	Approved by the FDA for invasive breast cancer. Worldwide sales of \$237 million in 2015 (see Related links)
Fingolimod	Transplant rejection	MS	2010	Pharmacological and structural analysis ¹¹	First oral disease-modifying therapy to be approved for MS. Global sales for fingolimod (Gilead) totalled \$3.3 billion in 2017 (see Related links)
Dapoxetine	Anxiety and depression	Premature ejaculation	2012	Pharmacological analysis	Approved in the UK and a number of European countries, still awaiting approval in the US. Peak sales are projected to reach \$760 million.
Topiramate	Epilepsy	Obesity	2012	Pharmacological analysis	Qsymia (Novartis) contains topiramate in combination with phentermine.
Ketocanazole	Fungal infections	Cushing syndrome	2014	Pharmacological analysis	Approved by the EMA for Cushing syndrome in adults and adolescents above the age of 12 years (see Related links)
Aspirin	Analgesia	Colorectal cancer	2015	Retrospective clinical and pharmacological analysis	US Preventive Services Task Force released draft recommendations in September 2015 regarding the use of aspirin to help prevent cardiovascular disease and colorectal cancer ¹² .

ADHD, attention deficit hyperactivity disorder; EMA, European Medicines Agency; FDA, US Food and Drug Administration; MS, multiple sclerosis; SUI, stress urinary incontinence.

Pushpakom, S., Iorio, F., Eyers, P. et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 18, 41–58 (2019)



Representation learning for networks in biology and medicine.

Li, Michelle M., Kexin Huang, and Marinka Zitnik. "Graph Representation Learning in Biomedicine." *arXiv preprint arXiv:2104.04883* (2021).





FIGURE 5 A diagram illustrating deep learning-based drug repurposing infrastructure for emerging development of host-targeting therapies to fight COVID-19 and future pandemic. We posited that approved drugs that specific human proteins/targets may offer potential host-targeting therapies for COVID-19 as COVID-19 may share biology with human cells and tissues from the SARS-CoV-2 virus-host protein-protein interactome perspective^{3,4,6}

Pan, Xiaoqin, et al. "Deep learning for drug repurposing: Methods, databases, and applications." *Wiley Interdisciplinary Reviews: Computational Molecular Science* (2022)


Disease and Biological Networks

- Networks is a method of representing systemic biological interactions between various biological objects.
- These networks or graphs are used to capture relationships between biological entities.




Protein-Protein Interaction Network of Heroin Use Disorder

Chen, S.J., Liao, D.L., Chen, C.H. et al. Construction and Analysis of Protein-Protein Interaction Network of Heroin Use Disorder. *Sci Rep* 9, 4980 (2019)



Human Disease Network

Goh, Kwang-Il, et al. "The human disease network." *Proceedings of the National Academy of Sciences* 104.21 (2007): 8685-8690.



Multi-scale Interactome Network

Ruiz, C., Zitnik, M. & Leskovec, J. Identification of disease treatment mechanisms through the multiscale interactome. *Nat Commun* 12, 1796 (2021)


Baricitinib

THE LANCET
Respiratory Medicine

frontiers
in Pharmacology

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

Vincent C Marconi, Athimelaipet V Ramanan, Stephanie de Bono, Cynthia E Kartman, Venkatesh Krishnan, Ran Liao, Mario Lucio B Pinzuti, Jason D Goldman, Jorge Alatorre-Alexander, Rita de Cassia Pellegrini, Vicente Estrada, Mousumi Som, Anabela Cardoso, Sujitra Chakladar, Brenda Crowe, Paulo Reis, Xin Zhang, David H Adams, E Wesley Ely, on behalf of the COV-BARRIER Study Group*




Baricitinib

- Originally used for rheumatoid arthritis (RA).
- Inhibitor of Janus Kinase (JAK).

Interpretation

Although there was no significant reduction in the frequency of disease progression overall, treatment with baricitinib in addition to standard of care (including dexamethasone) had a similar safety profile to that of standard of care alone, and was associated with reduced mortality in hospitalised adults with COVID-19.




Expert-Augmented Computational Drug Repurposing Identified Baricitinib as a Treatment for COVID-19

Daniel P. Smith¹, Olly Oechsle¹, Michael J. Rawling¹, Ed Savory¹, Alix M.B. Lacoste^{2†} and Peter John Richardson^{1*}

¹BenevolentAI, London, United Kingdom; ²BenevolentAI, Brooklyn, NY, United States

The workflow comprised rapid augmentation of knowledge graph information from recent literature using machine learning (ML) based extraction, with human-guided iterative queries of the graph. **Using this workflow, we identified the rheumatoid arthritis drug baricitinib as both an antiviral and anti-inflammatory therapy.** The effectiveness of baricitinib was substantiated by the recent publication of the data from the **ACT-2 randomised Phase 3 trial**, followed by **emergency approval for use by the FDA**, and a report from the CoV-BARRIER trial confirming significant reductions in mortality with baricitinib compared to standard of care



DrugCell


- DrugCell is an interpretable deep learning model that simulates the response of human cancer cells to therapy.
- DrugCell predictions might generalize to patient tumors and can be used to design synergistic drug combinations that significantly improve treatment outcomes.

Cancer Cell

Article


Predicting Drug Response and Synergy Using a Deep Learning Model of Human Cancer Cells

Graphical Abstract





Authors

Brent M. Kuenzi, Jiiso Park, Samson H. Fong, ..., Jason F. Kreisberg, Jianzhu Ma, Trey Ideker



interpretable hierarchical system

Gene Ontology DB
2,086 biological processes used 6 neurons per system



Kuenzi, Brent M., et al. "Predicting drug response and synergy using a deep learning model of human cancer cells." *Cancer cell* 38.5 (2020): 672-684.

Antibiotic discovery

Cell

Article

A Deep Learning Approach to Antibiotic Discovery






Figure 5. Halicin Displays Efficacy in Murine Models of Infection



Stokes, Jonathan M., et al. "A deep learning approach to antibiotic discovery." *Cell* 180.4 (2020): 688-702.

Discovery of **structurally divergent** antibiotics

- Here, we demonstrate how the combination of *in silico* predictions and empirical investigations can lead to the discovery of new antibiotics.
- First, we trained a deep neural network model to predict *growth inhibition of Escherichia coli using a collection of 2,335 molecules*.
- Second, we applied the resulting model to several *discrete chemical libraries, comprising >107 million molecules*, to identify potential lead compounds with activity against *E. coli*.
- After *ranking the compounds* according to the model's predicted score, we lastly selected a list of candidates based on a pre-specified prediction score threshold, chemical structure, and availability.
- Through this approach, from the Drug Repurposing Hub, we identified the c-Jun N-terminal kinase inhibitor SU3327 (De et al.,

Literature-based approaches

Bioinformatics, 36(4), 2020, 1234–1240
doi: 10.1093/bioinformatics/btad82
Advance Access Publication Date: 10 September 2019
Original Paper



Data and text mining

BioBERT: a pre-trained biomedical language representation model for biomedical text mining

Jinhyuk Lee ^{1,†}, Wonjin Yoon ^{1,†}, Sungdong Kim ², Donghyeon Kim ¹, Sunkyu Kim ¹, Chan Ho So ³ and Jaewoo Kang ^{1,3,*}

¹Department of Computer Science and Engineering, Korea University, Seoul 02841, Korea, ²Clova AI Research, Naver Corp, Seong-Nam 13561, Korea and ³Interdisciplinary Graduate Program in Bioinformatics, Korea University, Seoul 02841, Korea

Biomedical text mining is becoming increasingly important as the number of biomedical documents rapidly grows. With the progress in natural language processing (NLP), extracting valuable information from biomedical literature has gained popularity among researchers, and deep learning has boosted the development of effective biomedical text mining models. However, directly applying the advancements in NLP to biomedical text mining often yields unsatisfactory results due to a word distribution shift from general domain corpora to biomedical corpora. In this article, we investigate how the recently introduced pre-trained language model BERT can be adapted for biomedical corpora. We introduce BioBERT (Bidirectional Encoder Representations from Transformers for Biomedical Text Mining), which is a domain-specific language representation model pre-trained on large-scale biomedical corpora. With almost the same architecture across tasks, BioBERT largely outperforms BERT and previous state-of-the-art models in a variety of biomedical text mining tasks when pre-trained on biomedical corpora. While BERT obtains performance comparable to that of previous state-of-the-art models, BioBERT significantly outperforms them on the following three representative biomedical text mining tasks: biomedical named entity recognition (0.62% F1 score improvement), biomedical relation extraction (2.80% F1 score improvement) and biomedical question answering (12.24% MRR improvement). Our analysis results show that pre-training BERT on biomedical corpora helps it to understand complex biomedical texts. We make the pre-trained weights of BioBERT freely available at [this https URL](https://github.com/jinhyuklee/bioBERT), and the source code for fine-tuning BioBERT available at [this https URL](https://github.com/jinhyuklee/bioBERT).

Lee, Jinhyuk, et al. "BioBERT: a pre-trained biomedical language representation model for biomedical text mining." *Bioinformatics* 36.4 (2020): 1234-1240.

Literature-based approaches



Data and text mining


BioBERT: a pre-trained biomedical language representation model for biomedical text mining

Jinhyuk Lee^{1,2}, Wonjin Yoon^{1,2}, Sungdong Kim², Donghyeon Kim¹, Sunkyu Kim¹, Chan Ho So³ and Jaewoo Kang^{1,2,*}

¹Department of Computer Science and Engineering, Korea University, Seoul 02841, Korea, ²Clova AI Research, Naver Corp, Seong-Nam 12681, Korea and ³Interdisciplinary Graduate Program in Bioinformatics, Korea University, Seoul 02841, Korea

Table 1. List of text corpora used for BioBERT

Corpus	Number of words	Domain
English Wikipedia	2.5B	General
BooksCorpus	0.8B	General
PubMed Abstracts	4.5B	Biomedical
PMC Full-text articles	13.5B	Biomedical



Lee, Jinhyuk, et al. "BioBERT: a pre-trained biomedical language representation model for biomedical text mining." *Bioinformatics* 36.4 (2020): 1234-1240.

Literature-based approaches

PubMedBERT

Domain-Specific Language Model Pretraining for Biomedical Natural Language Processing

YU GU*, ROBERT TINN*, HAO CHENG*, MICHAEL LUCAS, NAOTO USUYAMA, XIAODONG LIU, TRISTAN NAUMANN, JIANFENG GAO, and HOIFUNG POON, Microsoft Research

BioMegatron

BioMegatron: Larger Biomedical Domain Language Model

Hoo-Chang Shin, Yang Zhang, Evelina Bakhturina, Raul Puri, Mostofa Patwary, Mohammad Shoeybi, Raghav Mani
 NVIDIA / Santa Clara, California, USA
 hshin@nvidia.com

Model	PubMed Corpus	#Words
BioBERT	abstracts	4.5 billion
PubMedBERT	abstracts + full-text	16.8 billion
BioMegatron	abstracts + full-text-CC	6.1 billion

Lee, Jinhyuk, et al. "BioBERT: a pre-trained biomedical language representation model for biomedical text mining." *Bioinformatics* 36.4 (2020): 1234-1240.

Gu, Yu, et al. "Domain-specific language model pretraining for biomedical natural language processing." *ACM Transactions on Computing for Healthcare (HEALTH)* 3.1 (2021): 1-23.

Shin, Hoo-Chang, et al. "BioMegatron: Larger biomedical domain language model." *arXiv preprint arXiv:2010.06060* (2020).

Networks

Commonly used biological networks and disease networks

- Protein-protein interaction network (PPI) – STRING, BioGRID
- Biological pathways network – KEGG, Reactome
- Disease networks – Disasome, HDN, DGN
- Comprehensive heterogeneous network – HetioNet, MSI


PPI Network - STRING

STRING

- Search Tool for the Retrieval of Interacting Genes/Proteins
- Integrates all publicly available sources of protein-protein interaction information.
 - Automated text mining
 - Interaction experiments
 - Computational interaction predictions from co-expression
- Statistics of latest version of STRING

Category	Count
Organisms	14,094
Proteins	67,592,464
Interactions	20,052,394,041

Browse COL5A1 protein in STRING



Szklarczyk, Damian et al. "The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets." *Nucleic acids research* vol. 49,D1 (2021)

PPI Network - BioGRID **BioGRID 4.4**

BioGRID

- Biological General Repository for Interaction Datasets
- Archives genetic and protein interaction data from various organisms.

Category	Count
Protein/Genetic interactions	2,551,504
Chemical interactions	29,417
Post translational modifications	1,128,339

Browse HMGR protein in BioGRID


Oughtred, Rose et al. "The BioGRID database: A comprehensive biomedical resource of curated protein, genetic, and chemical interactions." *Protein science : a publication of the Protein Society* vol. 30,1 (2021)

Biological Pathways Network - KEGG

KEGG

- Kyoto Encyclopedia of Genes and Genomes
- A curated collection of biological information compiled from published material.
- Includes information on genes, proteins, metabolic pathways, molecular interactions, and biochemical reactions associated with specific organisms.
- Provides a relationship for how these components are organized in a cellular structure or reaction pathway.

p53 signaling pathway from KEGG



Kanehisa, Minoru et al. "KEGG for taxonomy-based analysis of pathways and genomes." *Nucleic acids research*, gkac963. 27 Oct. 2022

Statistics of KEGG

KEGG Database as of 2022/11/15		
Systems information		
KEGG PATHWAY	Pathway maps, reference (total)	560 (981,813)
KEGG BRITE	Functional hierarchies, reference (total)	189 (331,224)
KEGG MODULE	KEGG modules	470
	Reaction modules	46
Genomic information		
KEGG ORTHOLOGY	KEGG Orthology (KO) groups	25,499
KEGG GENES	Genes in KEGG organisms	43,807,605
	Viral genes	595,443
	Viral mature peptides	312
	Addendum proteins	4,125
KEGG GENOME	KEGG organisms (817 eukaryotes, 7310 bacteria, 401 archaea)	8,528
	KEGG selected viruses (14 category)	359
	KEGG viruses (Vtax category)	11,485
Chemical information		
KEGG COMPOUND	Metabolites and other chemical substances	19,017
KEGG GLYCAN	Glycans	11,114
KEGG REACTION	Biochemical reactions	11,858
	Reaction class	3,192
KEGG ENZYME	Enzyme nomenclature	8,012
Health information		
KEGG NETWORK	Disease-related network elements	1,310
	Network variation maps	146
KEGG VARIANT	Human gene variants	802
KEGG DISEASE	Human diseases	2,603
KEGG DRUG	Drugs	12,004
	Drug groups	2,410
Drug labels		
KEGG MEDICUS	Japanese prescription drug labels from JAPIC	14,138
	Japanese OTC drug labels from JAPIC	10,638
KEGG MEDICUS	FDA prescription drug labels linked to DailyMed	34,227

Biological Pathways Network - Reactome




Reactome

- Open source pathway database
- Curated human pathways encompassing metabolism, signaling, and other biological processes.
- Every pathway is traceable to primary literature.
- Cross-reference to many other bioinformatics databases.
- Provides data analysis and visualization tools.

Statistics of Reactome



SPECIES	PROTEINS	COMPLEXES	REACTIONS	PATHWAYS
S. pombe	1690	1805	1486	819
S. cerevisiae	1913	1827	1566	812
D. rerio	8633	8452	7383	1676
X. tropicalis	7046	7321	6159	1580
G. gallus	7296	7931	6859	1706
S. scrofa	8407	8825	7548	1660
B. taurus	8841	9182	8048	1696
C. familiaris	8162	8725	7455	1657
R. norvegicus	8808	9505	8356	1702
M. musculus	9537	10620	9456	1715
*H. sapiens	11097	14084	14398	2601
D. melanogaster	4755	5402	4596	1477
C. elegans	4468	4403	3700	1304
D. discoideum	2681	2502	2313	982
P. falciparum	1051	1007	861	599

Browse Signal Transduction pathway in Reactome



Gillespie, Marc et al. "The reactome pathway knowledgebase 2022." *Nucleic acids research* vol. 50,D1 (2022)

Disease Networks – Diseasome, HDN and DGN



Diseasome

- A small subset of OMIM-based disease gene association.

HDN: Human Disease Network

- Projection of the diseasome bipartite graph.
- Two diseases are connected if there is a gene that is implicated in both.

DGN: Disease Gene Network



- Two genes are connected if they are involved in the same disease.

Goh, Kwang-Il, et al. "The human disease network." *Proceedings of the National Academy of Sciences* 104.21 (2007): 8685-8690.


Comprehensive Heterogeneous Networks - HetioNet



- An integrative network encoding knowledge from millions of biomedical studies.
- Data were integrated from 29 public resources to connect meta-nodes.
- Meta nodes (11 types): anatomy, biological process, cellular component, compound, disease, gene, molecular function, pathway, pharmacologic class, side effect, symptom
- Meta edges (24 types)



Hetionet Web Interface





Himmelstein, Daniel Scott et al. "Systematic integration of biomedical knowledge prioritizes drugs for repurposing." eLife vol. 6 e26726. 22 Sep. 2017

Comprehensive Heterogeneous Networks - MSI



- Multiscale Interactome network
- An integrative network of disease, proteins, biological functions and drugs.
- Data were retrieved from 19 public databases.
- Random walk-based method can be applied to capture the effects of drugs through a hierarchy of biological functions and protein-protein interactions.



Ruiz, C., Zitnik, M. & Leskovec, J. Identification of disease treatment mechanisms through the multiscale interactome. Nat Commun 12, 1796 (2021)

Databases

Commonly used databases for Drug repositioning

Drug Repurposing Hub
repoDB
CTD
PharmacODB

Database Overview (graph view)




Figure 1. Drug repositioning databases categorized into more than one subcategory. Some subcategories are shown more than once in order to facilitate the interpretation of database relationships.

Tanoli, Ziaurrehman, et al. "Exploration of databases and methods supporting drug repurposing: a comprehensive survey." *Briefings in bioinformatics* 22.2 (2021): 1656-1678.

Database Overview (table view)

TABLE 1 The widely used databases in drug repurposing

Database	Describe	URL	References	API
BindingDB	A public database of protein-ligand binding affinities.	http://www.bindingdb.org/bind	30	*
CCLE	Cancer Cell Line Encyclopedia (CCLE) is a large cancer cell line collection that broadly captures the genetic diversity of human cancers and provides valuable insight into anti-cancer drug responses.	https://portals.broadinstitute.org/ccle	31	NA
CellMinerCDB	An interactive web application that simplifies the access and exploration of cancer cell line pharmacogenomic data across different sources.	https://discover.nci.nih.gov/cellminerdb/	32	NA
CHEMBL	A manually curated database of bioactive molecules with drug-like properties. It brings together chemical, bioactivity, and genomic data to aid the translation of genomic information into effective new drugs.	https://www.ebi.ac.uk/chembl/	33	*
ChemDB	It provides chemical structures and molecular properties. ChemDB also provides 3D structures of molecules.	http://tox.its.uct.edu/	34	NA
ChemicalChecker	It provides processed, harmonized, and integrated bioactivity data.	https://chemicalchecker.org/	35	*
CGI	Cancer Genome Interpreter (CGI) supports the identification of tumor alterations that drive the disease and flag those that may be therapeutically actionable.	https://www.cancergenomeinterpreter.org/	36	NA
CTD (Comparative Toxicogenomics Database)	Comparative Toxicogenomics Database (CTD) provides manually curated information about chemical-gene or protein interactions, chemical-disease, and gene-disease relationships.	http://ctdbase.org/	37	NA
DCIdb	Drug-target interactions mined from >30 treated sources, including DrugBank, PharmGKB, ChEMBL, Drug Target Commons, and Therapeutic Target Database.	http://www.dgidb.org/	38	*
DrugNET	It is a discovery platform containing publicly available collections of genes and variants associated with human diseases.	http://www.drugnet.org/	39	*
DrugBank	It combines drug data (i.e., chemical, pharmacological and pharmaceutical) information with drug target information (i.e., sequence, structure, and pathway).	http://www.drugbank.ca	28	*
DrugCentral	It provides information on active chemical entities and drug modes of action.	http://drugcentral.org/	40	*
DTC	Drug Target Commons (DTC) manually curates bioactivity data along with protein classification into superfamilies, clinical phase, and adverse effects as well as disease indications.	http://drugtargetcommons.com/	41	*
DTP	Drug Target Profiler (DTP) contains drug target bioactivity data and implements network visualizations. DTP also contains cell based response profiles of the drugs and their clinical phase information.	http://drugtargetprofiler.com/	42	NA
GeneCards	Automatically integrates gene-centric data from 150 web sources, including genomic, transcriptomic, proteomic, genetic, clinical, and functional information.	http://www.genecards.org/	43	NA
GLIDA	It contains drug-target interactions for G-protein-coupled receptors (GPCRs).	http://pharmids.pharm.kyoto-u.ac.jp/ncvts/glide/	44	NA
QepDB	It contains quantitative bioactivity data for approved drugs and investigational compounds.	http://www.qepdbpharmacology.org/	45	*


TABLE 1 (Continued)

Database	Describe	URL	References	API
KEGG	It is a knowledge base for systematic analysis of gene functions, linking genomic information with higher order functional information.	http://www.genome.jp/kegg	27	*
LINCS	It contains details about the drug assays, cell types, and perturbagens that are currently part of the library, as well as software that can be used for analyzing the data.	http://www.lincsproject.org/LINCS/	46	*
OMIM	It is a comprehensive, authoritative compendium of human genes and genetic phenotypes that is freely available and updated daily. The full-text, referenced overview in OMIM contains information on all known Mendelian disorders and over 16,000 genes, and it focuses on the relationship between phenotype and genotype.	https://www.omim.org/	47	*
PathBank	PathBank is designed specifically to support pathway elucidation and discovery in transcriptomics, proteomics, metabolomics, and systems biology.	https://pathbank.org/	48	NA
PathwayCommon	Pathways including biochemical reactions, complex assembly, and physical interactions involving proteins, DNA, RNA, small molecules, and complexes.	http://www.pathwaycommons.org/	49	*
PZSP Ki	It contains bioactivity data in terms of k, especially for GPCRs, ion channels, transporters, and enzymes.	https://pdsdb-unc.edu/pdspWeb/	50	*
PharmGKB	It contains comprehensive data on genetic variation on drug response for clinicians and researchers.	https://www.pharmgkb.org/	51	*
Probes & Drugs Portal	A public resource joining together focused libraries of bioactive compounds (e.g., probes, drugs, specific inhibitor sets).	https://www.probesdrugs.org/home/	52	NA
Pubchem	It provides varieties of molecular information including the chemical structure and physical properties, biological activities, safety and toxicity information, patents, literature citations, and so on.	https://pubchem.ncbi.nlm.nih.gov/	29	*
STITCH	It stores known and predicted interactions of chemicals and proteins, and currently covers 9,643,763 proteins from 2031 organisms.	http://stitch.embl.de/	53	*
Supertarget	A data resource is used for analyzing drug-target interactions and drug side effects.	http://bioinf-spache.charite.de/supertarget/	54	NA
SwissTarget-Prediction	It contains information on predicted targets of drugs based on the similarity principle through reverse screening.	http://www.swisstargetprediction.ch/	55	NA
TTD	Therapeutic Target Database (TTD) provides information about the known and explored therapeutic protein and nucleic acid targets, the targeted disease, pathway information, and the corresponding drugs directed at each of these targets.	https://db.idrblab.org/td/	56	NA

API, Application Programming Interface. *Indicates that the dataset provides API. NA indicates that there is no API in the dataset.

Pan, Xiaojin, et al. "Deep learning for drug repurposing: Methods, databases, and applications." *Wiley Interdisciplinary Reviews: Computational Molecular Science* (2022)

Databases: Drug Repurposing Hub



Drug Repurposing Hub


- A curated and annotated collection of FDA-approved drugs, clinical trial drugs, and pre-clinical tool compounds with a companion information resource.
- Hand-curated collection of compounds were experimentally confirmed and annotated with literature-reported targets.
- Each drug information includes compound name, clinical phase, mechanism of action, and protein target.

Statistics of Drug Repurposing Hub

Category	Count
Total samples	16,826
Protein targets	2,183
Unique compounds	7,934
Drug indications	670

Browse Sildenafil in Drug Repurposing Hub Web app

Sildenafil



[View samples for compound](#)

Broad Batch ID
BRD-K79759585-048-07-1

Clinical phase
Launched

Disease area
erectile dysfunction (urology)

Mechanism of Action
phosphodiesterase inhibitor

Targets (5)
PDE5A, SLC01B1, SLC01B3

Source: DrugBank, IUPHAR, TTD

PubChem ID
135398744

Expected mass:
474.205

InChIKey
BNRNXLJZRGQAQC-UHFFFAOYSA-N

SMILES
CCCC1=NC(Cc2c1nc([nH]c2=O)-c1ccc1OCC(S)=O)-[O-]N1CCN(C)CC1



Orange Book
Ingredients: SILDENAFIL CITRATE

Approval Date	Number	Applicant
Mar 27, 1998	020895	PFIZER INC

Patent Expiration Date	Number	Patent Use
Apr 22, 2020	64669012*PED	

External Links: [Drugbank](#) | [IUPHAR](#) | [TTD](#) | [CHEMBL](#)

Target Protein Class



Corsello, Steven M et al. "The Drug Repurposing Hub: a next-generation drug library and information resource." *Nature medicine* vol. 23,4 (2017)



Databases: repoDB



repoDB

- A standard set of drug repositioning successes and failures that can be used to fairly and reproducibly benchmark computational repositioning methods.
- Data were extracted from DrugCentral and ClinicalTrials.gov.
- Each drug information includes compound name, clinical phase and disease name.

Statistics of repoDB



Category (status)	Drug count
Approved	2,162
Suspended	78
Terminated	518
Withdrawn	336

Brown, A., Patel, C. A standard database for drug repositioning. *Sci Data* 4, 170029 (2017)

Databases: CTD




Curated Exposure Statements	204,467
Unique Chemicals	1,500
Unique Genes	1,084
Unique Diseases	488
Unique GO Terms	484
Curated Exposure References	3,300

CTD

- Comparative Toxicogenomics Database
- Provides manually curated information about chemical-gene or protein interactions, chemical-disease, and gene-disease relationships.
- Recent version of CTD offers a CTD Tetramer tool that generates potential molecular mechanistic pathways.

CTD Tetramer tool



Browse Sildenafil in CTD Web app

Sildenafil Citrate

Definition: A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.

Top Interacting Genes:

Gene	Interactions
FDESA	20
NO53	18
ACT	15
ICL2	12
BAX	10
HMOX1	8
CASP8	7
PRKG1	6
VEGFA	5
NO51	4

MeSH ID: D000068677

External Links: PubChem, D000068677

Ancestors:

1. Chemicals -- Organic Chemicals H T C @ -- Amides H T C @ -- Sulfonamides H T C @ -- Sildenafil Citrate H T C
2. Chemicals -- Organic Chemicals H T C @ -- Sulfur Compounds H T C @ -- Sulfenes H T C @ -- Sulfonamides H T C @ -- Sildenafil Citrate H T C
3. Chemicals -- Heterocyclic Compounds H T C @ -- Heterocyclic Compounds, 1-Ring H T C @ -- Piperazines H T C @ -- Sildenafil Citrate H T C
4. Chemicals -- Heterocyclic Compounds H T C @ -- Heterocyclic Compounds, Fused-Ring H T C @ -- Heterocyclic Compounds, 2-Ring H T C @ -- Purines H T C @ -- Sildenafil Citrate H T C

Davis, Allan Peter et al. "Comparative Toxicogenomics Database (CTD): update 2023." *Nucleic acids research*, gkac833. 28 Sep. 2022

Databases: PharmacoDB

PharmacoDB

- A web-application database that integrates multiple cancer pharmacogenomics datasets profiling approved and investigational drugs across cell lines from diverse tissue types.
- Offers a standardized cell line, drug identifiers and data format for drug sensitivity measurements.
- Included cell line data from..
 - CCLE, CTRPv2, FIMM, GDSC1, GDSC2, GRAY, NCI60, PRISM, UHNBreast, gCSI

Browse Paclitaxel in PharmacoDB Web app

Paclitaxel FDA Approval Status: Approved

Synonyms		
Sources	Names Used	
CCLE, FIMM, GDSC1, GDSC2, GRAY, NCI60	Paclitaxel	
CTRPv2, PRISM, UHNBreast	paclitaxel	
gCSI	paclitaxel//Paclitaxel	
Standardized name in PharmacoSet	Paclitaxel	

Identifiers	
SMILES	CC1=OCC2=C(C3=C(C=C1)C(=O)C=C3)OC(=O)C4=CC=CC=C4
InChIKey	RCINICONZJXQF-MZKDDVADSA-N

Number of cell lines tested with Paclitaxel (per dataset)

Number of tissues tested with Paclitaxel (per dataset)

Statistics of PharmacoDB



Feizi, Nikta et al. "PharmacoDB 2.0: improving scalability and transparency of in vitro pharmacogenomics analysis." *Nucleic acids research* vol. 50,D1 (2022)

Technology

Network analysis technologies

Network analysis technologies

Analytical algorithms describing human gene networks have been developed for three major tasks in disease research:

1. Disease gene prioritization,
2. Disease module discovery, and
3. Stratification of complex diseases.

Network-based Drug Repurposing Technologies

SNF-cVAE (Knowledge-Based Systems, 2021)

CBPred (Cells, 2019)

DeepDR (Bioinformatics, 2019)

BiFusion (ISMB 2020)

Semantic Teleport (in revision)

The Main Issue for Network-based Drug Repurposing

Discover drug-disease relationship using

- Drug network
- Gene network
- Disease network

Hetionet database:

- drug-drug network: 1552 nodes, 6,486 edges
- disease-disease network: 137 nodes, 543 edges
- **gene-gene network: 20,945 nodes, ~200,000 edges**
- drug-gene edges: ~50,000
- disease-gene edges: ~30,000

Major Issues for Drug Repurposing

- There are multiple ways to learn embedding vectors for drug
 - Drug-centered embeddings from Drug-drug, Drug-target, Drug-disease.
 - Then, **how to combine different views on drugs?**
- Three-way relationship among drug-gene-disease cannot be learned at once.
- In the end, we need to deduce **drug-disease binary relationship**.
 - Basically, binary relationships are somehow combined on different layers, hierarchically.

Network-based Drug Repurposing Technologies

SNF-cVAE (Knowledge-Based Systems, 2021)

CBPred (Cells, 2019)

DeepDR (Bioinformatics, 2019)

BiFusion (ISMB 2020)

Semantic Teleport (BioRxiv. In review)

Network-based Drug Repurposing: Cases

Knowledge-Based Systems 212 (2021) 106585



Contents lists available at ScienceDirect

Knowledge-Based Systems

journal homepage: www.elsevier.com/locate/knosys



SNF-CVAE: Computational method to predict drug–disease interactions using similarity network fusion and collective variational autoencoder



Tamer N. Jarada^a, Jon G. Rokne^a, Reda Alhajj^{a,b,c,*}

^a Department of Computer Science, University of Calgary, Calgary, Alberta, Canada

^b Department of Computer Engineering, Istanbul Medipol University, Istanbul, Turkey

^c Department of Health Informatics, University of Southern Denmark, Odense, Denmark

Jarada, Tamer N., Jon G. Rokne, and Reda Alhajj. "SNF-CVAE: computational method to predict drug–disease interactions using similarity network fusion and collective variational autoencoder." *Knowledge-Based Systems* 212 (2021): 106585.

Network-based Drug Repurposing: Cases


SNF-CVAE

- Input:
 - Drug-related similarity information
 - Drug-disease interactions
- Method:
 - **Similarity network fusion (SNF)**
 - **Drug similarity network** using drug-related data sets and drug-disease interaction dataset.
 - **Collective variational autoencoder (CVAE)**
 - **Training cVAE** with drug similarity (from above) and drug-disease interaction.
- Predicted drug candidates for potentially treating Alzheimer’s disease and Juvenile rheumatoid arthritis.

Jarada, Tamer N., Jon G. Rokne, and Reda Alhaji. "SNF-CVAE: computational method to predict drug–disease interactions using similarity network fusion and collective variational autoencoder." *Knowledge-Based Systems* 212 (2021): 106585.

Network-based Drug Repurposing: Cases

SNF-CVAE



Jarada, Tamer N., Jon G. Rokne, and Reda Alhaji. "SNF-CVAE: computational method to predict drug–disease interactions using similarity network fusion and collective variational autoencoder." *Knowledge-Based Systems* 212 (2021): 106585.

Network-based Drug Repurposing: Cases



Article

Convolutional Neural Network and Bidirectional Long Short-Term Memory-Based Method for Predicting Drug–Disease Associations

Ping Xuan ¹, Yilin Ye ^{1,*}, Tiangang Zhang ^{2,*}, Lianfeng Zhao ¹ and Chang Sun ¹

¹ School of Computer Science and Technology, Heilongjiang University, Harbin 150080, China

² School of Mathematical Science, Heilongjiang University, Harbin 150080, China

* Correspondence: YeYilinCN@outlook.com (Y.Y.); tiangang_zhang01@126.com (T.Z.);
Tel.: +86-132-4840-5705 (Y.Y.); +86-188-4503-0636 (T.Z.)

Xuan, Ping, et al. "Convolutional neural network and bidirectional long short-term memory-based method for predicting drug–disease associations." *Cells* 8.7 (2019): 705.

Network-based Drug Repurposing: Cases


CBPred

- Input:
 - Drug similarity matrix (fingerprint-based)
 - Disease similarity matrix (MeSH-based)
- Goal:
 - Enrich paths between drugs and diseases
- Method:
 - **Convolutional Neural Network (CNN)**
 - Learn the association representation of drug-disease pairs from their similarities and associations.
 - **Bidirectional LSTM (BiLSTM)**
 - Learns path representation of drug-disease pair.
- Provided a list of novel drug-disease associations for drug repositioning

Xuan, Ping, et al. "Convolutional neural network and bidirectional long short-term memory-based method for predicting drug–disease associations." *Cells* 8.7 (2019): 705.

Network-based Drug Repurposing: Cases

CBPred



R and D are easily constructed by comparing rows and columns as vectors.
A is from prior knowledge.

Figure 1. Construction of drug-disease heterogeneous network DrDisNet. R and D are the similarity matrix of drugs and diseases, respectively. A is the association matrix between drugs and diseases, while A^T is the transpose of A.

Xuan, Ping, et al. "Convolutional neural network and bidirectional long short-term memory-based method for predicting drug-disease associations." *Cells* 8.7 (2019): 705.

Network-based Drug Repurposing: Cases

CBPred





Figure 2. Construction of the framework based on the convolutional neural network and bidirectional long short-term memory for learning the original and path representations.

Xuan, Ping, et al. "Convolutional neural network and bidirectional long short-term memory-based method for predicting drug-disease associations." *Cells* 8.7 (2019): 705.

Network-based Drug Repurposing: DeepDR

Bioinformatics



JOURNAL ARTICLE

deepDR: a network-based deep learning approach to *in silico* drug repositioning

Xiangxiang Zeng, Siyi Zhu, Xiangrong Liu, Yadi Zhou, Ruth Nussinov, Feixiong Cheng 

[Author Notes](#)

Bioinformatics, Volume 35, Issue 24, 15 December 2019, Pages 5191–5198,

<https://doi.org/10.1093/bioinformatics/btz418>

Published: 22 May 2019 **Article history** ▼


Zeng, Xiangxiang, et al. "deepDR: a network-based deep learning approach to *in silico* drug repositioning." *Bioinformatics* 35.24 (2019): 5191-5198.

Network-based Drug Repurposing: DeepDR

- **Input:** Integrated network of 10 different networks:
 - one drug-disease,
 - one drug-side-effect,
 - one drug-target and
 - seven drug-drug networks
- **Method:** A three-step approach for drug repurposing
 - 1. Random walk-based representation of 10 networks**
 1. Probabilistic co-occurrence matrix construction by random walks
 2. Shifted pointwise mutual information (PPMI) → **factorization of co-occurrence matrix** for network representation.
 - 2. Multi-modal deep autoencoder (MDA) based network fusion** of 10 network representations
 - 3. Collective VAE** for new drug-disease association prediction: uses
 1. Extracted features from MDA (side (*auxiliary?*) information)
 2. Known drug-disease associations
- The predicted drug-disease associations were validated by the *ClinicalTrials.gov* database

Zeng, Xiangxiang, et al. "deepDR: a network-based deep learning approach to *in silico* drug repositioning." *Bioinformatics* 35.24 (2019): 5191-5198.

Network-based Drug Repurposing: DeepDR



Zeng, Xiangxiang, et al. "deepDR: a network-based deep learning approach to *in silico* drug repositioning." *Bioinformatics* 35.24 (2019): 5191-5198.

Network-based Drug Repurposing: BiFusion

Bioinformatics



JOURNAL ARTICLE

Toward heterogeneous information fusion: bipartite graph convolutional networks for *in silico* drug repurposing

Zichen Wang, Mu Zhou ✉, Corey Arnold ✉ Author Notes

Bioinformatics, Volume 36, Issue Supplement_1, July 2020, Pages i525–i533,

<https://doi.org/10.1093/bioinformatics/btaa437>

Published: 13 July 2020

Wang, Zichen, Mu Zhou, and Corey Arnold. "Toward heterogeneous information fusion: bipartite graph convolutional networks for *in silico* drug repurposing." *Bioinformatics* 36. Supplement_1 (2020): i525-i533.

Network-based Drug Repurposing: BiFusion


BiFusion (Wang et al., ISMB 2020)

- **Input:**
 - Drug-protein-disease heterogeneous network
- **Method: 3-step deep learning framework**
 - **A bipartite GCN encoder for drug-disease pair embedding**
 - **Bipartite graph attention to protein** (*gene or protein centric*)
 - disease → protein
 - drug → protein
 - **Bipartite graph attention from protein** (*gene or protein centric*)
 - protein → disease
 - protein → drug

Wang, Zichen, Mu Zhou, and Corey Arnold. "Toward heterogeneous information fusion: bipartite graph convolutional networks for in silico drug repurposing." *Bioinformatics* 36.Supplement_1 (2020): i525-i533.

Network-based Drug Repurposing: BiFusion

BiFusion (Wang et al., ISMB 2020)



Wang, Zichen, Mu Zhou, and Corey Arnold. "Toward heterogeneous information fusion: bipartite graph convolutional networks for in silico drug repurposing." *Bioinformatics* 36.Supplement_1 (2020): i525-i533.

Network-based Drug Repurposing: DREAMwalk

DREAMwalk (Bang et al., *in revision*)



Multi-layer guilt-by-association-based drug repurposing by integrating clinical knowledge on biological heterogeneous networks

Dongmin Bang^{1,2}, Sangsoo Lim³, Sangseon Lee⁴, and Sun Kim^{1,5,6*}

¹Interdisciplinary Program in Bioinformatics, Seoul National University, Seoul, Republic of Korea

²AIGENDRUG Co., Ltd., Seoul, Republic of Korea

³Bioinformatics Institute, Seoul National University, Seoul, Republic of Korea

⁴Institute of Computer Technology, Seoul National University, Seoul, Republic of Korea

⁵Department of Computer Science and Engineering, Seoul National University, Seoul, Republic of Korea


⁶Interdisciplinary Program in Artificial Intelligence, Seoul National University, Seoul, Republic of Korea

*For whom the correspondence should be: sunkim.bioinfo@snu.ac.kr

Network-based Drug Repurposing: DREAMwalk

DREAMwalk (Bang et al., *in preparation*)


- Input:
 - Drug-gene-disease heterogeneous network
- Method:
 - *Semantic multi-layer Guilt-by-association*
 - Implemented by random walk with **clinical knowledge-guided teleport**
 - Teleport is performed to semantically similar neighbor drug/diseases



Network-based Drug Repurposing: DREAMwalk

DREAMwalk (Bang et al., *in preparation*)


- Method overview



Network-based Drug Repurposing: DREAMwalk

DREAMwalk (Bang et al., *in preparation*)

- Results:
 - State-of-the-art drug-disease association prediction
 - Harmonious embedding space of both clinical and biological contexts



Network-based Drug Repurposing: DREAMwalk

DREAMwalk (Bang et al., *in preparation*)

- Results:
 - Drug repurposing for breast carcinoma and Alzheimer's disease: well supported by literatures

Breast Carcinoma					
Rank	Drug	Original Indication	Avg. prob.	SD	Evidences
1	Hydroxyurea	CML, cancer of head and neck, sickle cell anemia	0.9868	0.028	56-59
2	Irinotecan	Colorectal cancer, SCLC, NSCLC	0.9854	0.021	60-62
3	Carmustine	Brain tumors, multiple myeloma, Hodgkin disease, NHL	0.9851	0.026	63,64
4	Clofarabine	ALL	0.9817	0.022	65,66
7	Etoposide	Germ cell tumors, Kaposi sarcoma, SCLC	0.9777	0.038	61,64
9	Vinblastine	Hodgkin disease, Lymphoma, NHL	0.9722	0.037	61,64
10	Erlotinib	NSCLC, Pancreatic cancer	0.9711	0.069	67-69

Alzheimer's disease					
Rank	Drug	Original Indication	Avg. prob.	SD	Evidences
1	Melatonin	Blind vision, sleep disorders	0.9953	0.006	70,71
3	Amantadine	Extrapyramidal disorders, Parkinson's disease	0.9926	0.016	72,73
4	Piribedil	Dizziness, Parkinson's disease	0.9887	0.018	74-76
7	Pramipexole	Parkinson's disease, restless legs syndrome	0.9822	0.027	77-79
9	Phenibut	Anxiety	0.9809	0.042	80,81
10	Fluoxetine	Bipolar disorder, Depressive disorder	0.9799	0.036	82,83

Summary of Drug Repurposing

- There are multiple ways to learn embedding vectors for drug
 - Drug-centered embeddings from Drug-drug, Drug-target, Drug-disease.
 - Then, how to combine different views on drugs?
 - **deepDR**: Multi-modal deep autoencoder
 - **SNF-cVAE**: similarity network fusion
 - **DreamWalk**: semantic random walks
- Three-way relationship among drug-gene-disease cannot be learned at once.
- In the end, we need to deduce **drug-disease binary relationship**.
 - Basically, binary relationships are somehow combined on different layers, hierarchically.
 - **deepDR**: Multi-modal deep autoencoder; then cVAE for drug-disease
 - **SNF-cVAE**: similarity network fusion; then cVAE for drug-disease
 - **BiFusion**: protein-centric bipartite graph attention twice; then MLP for drug-disease
 - **Zhang, Zhao et. al**: row pairing from drug-drug, drug-disease, disease-drug matrices; path generation by aligning paired vectors; then CNN + LSTM for drug-disease
 - **DreamWalk**: semantic random walks; then drug-disease embedding in the same space; then similarity between drug vector and disease vector for drug-disease

감사합니다!